CN108159032A - 二甲双胍在制备预防和/或治疗阿片类毒品成瘾药物中的应用和药物及制备方法 - Google Patents
二甲双胍在制备预防和/或治疗阿片类毒品成瘾药物中的应用和药物及制备方法 Download PDFInfo
- Publication number
- CN108159032A CN108159032A CN201810067882.1A CN201810067882A CN108159032A CN 108159032 A CN108159032 A CN 108159032A CN 201810067882 A CN201810067882 A CN 201810067882A CN 108159032 A CN108159032 A CN 108159032A
- Authority
- CN
- China
- Prior art keywords
- drug
- melbine
- opium
- prevention
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 49
- 229940079593 drug Drugs 0.000 title claims abstract description 41
- 239000008896 Opium Substances 0.000 title claims abstract description 28
- 229960001027 opium Drugs 0.000 title claims abstract description 28
- 208000011117 substance-related disease Diseases 0.000 title claims abstract description 26
- 230000002265 prevention Effects 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 206010013663 drug dependence Diseases 0.000 title abstract description 11
- 239000000463 material Substances 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 239000008223 sterile water Substances 0.000 claims description 4
- 239000000945 filler Substances 0.000 claims description 3
- 239000003182 parenteral nutrition solution Substances 0.000 claims description 3
- -1 sorbefacient Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 235000013355 food flavoring agent Nutrition 0.000 claims description 2
- 235000003599 food sweetener Nutrition 0.000 claims description 2
- 239000006193 liquid solution Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000000049 pigment Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 239000003765 sweetening agent Substances 0.000 claims description 2
- 239000007767 bonding agent Substances 0.000 claims 1
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 abstract description 23
- 229960005181 morphine Drugs 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 6
- 230000008485 antagonism Effects 0.000 abstract description 5
- 230000006399 behavior Effects 0.000 abstract description 4
- 239000000654 additive Substances 0.000 abstract description 3
- 230000000996 additive effect Effects 0.000 abstract description 2
- 230000006870 function Effects 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 22
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 13
- 229960003105 metformin Drugs 0.000 description 9
- 230000002496 gastric effect Effects 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 238000001784 detoxification Methods 0.000 description 3
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- 229920002527 Glycogen Polymers 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229940121954 Opioid receptor agonist Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 208000008013 morphine dependence Diseases 0.000 description 2
- 239000003402 opiate agonist Substances 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- PLRACCBDVIHHLZ-UHFFFAOYSA-N 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Chemical compound C1N(C)CCC(C=2C=CC=CC=2)=C1 PLRACCBDVIHHLZ-UHFFFAOYSA-N 0.000 description 1
- 101150033839 4 gene Proteins 0.000 description 1
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
- 238000010175 APPswe/PSEN1dE9 Methods 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 230000006974 Aβ toxicity Effects 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 208000018152 Cerebral disease Diseases 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 102000018711 Facilitative Glucose Transport Proteins Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108091052347 Glucose transporter family Proteins 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101001135571 Mus musculus Tyrosine-protein phosphatase non-receptor type 2 Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 102000003802 alpha-Synuclein Human genes 0.000 description 1
- 108090000185 alpha-Synuclein Proteins 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 229960002069 diamorphine Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000006377 glucose transport Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960001797 methadone Drugs 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 229960005195 morphine hydrochloride Drugs 0.000 description 1
- XELXKCKNPPSFNN-BJWPBXOKSA-N morphine hydrochloride trihydrate Chemical compound O.O.O.Cl.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O XELXKCKNPPSFNN-BJWPBXOKSA-N 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 1
- 229960003086 naltrexone Drugs 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 239000003401 opiate antagonist Substances 0.000 description 1
- 229940124636 opioid drug Drugs 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000000192 social effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012549 training Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开二甲双胍在制备预防和/或治疗阿片类毒品成瘾药物中的应用和药物及制备方法,涉及医药技术领域。二甲双胍具有拮抗吗啡所引起的位置偏爱行为的作用,可用于阿片类毒品成瘾的预防及治疗,进一步扩宽了二甲双胍的应用范围,克服技术偏见,具有疗效显著、安全性高、无成瘾性、无副作用、价格低廉,可以减轻病人的经济负担的优势,对于临床上预防或治疗阿片类毒品成瘾有重要意义。
Description
技术领域
本发明提供一种二甲双胍的应用,尤其是二甲双胍在制备预防和/或治疗阿片类毒品成瘾药物中的应用,还涉及该药物及其制备方法,属于医药领域。
背景技术
阿片类毒品滥用是当今世界上的社会公害之一。常见的阿片类毒品包括吗啡(morphine)、海洛因和鸦片等。阿片类毒品成瘾是指反复多次使用阿片类毒品后,可形成精神依赖和躯体依赖,并且停药后会出现严重的戒断症状,是一种慢性复发性脑疾病。对阿片类毒品成瘾的治疗方法是戒毒,其由脱毒、防复发和回归社会等三个有机联系的环节构成。脱毒是戒毒治疗的基础,特指为减轻吸毒者停掉毒品后出现的戒断反应,给予戒毒者以药物治疗或控制其出现的戒毒反应的过程。目前,戒毒药物主要有包括:阿片受体激动剂,如美沙酮,实为阿片类药物替代疗法;非阿片受体激动剂,如可乐定,缓解戒断症状;阿片受体拮抗剂,如纳曲酮,用于脱毒后防复吸;中药类戒毒药。虽然这些药物对阿片类毒品成瘾戒断有不同的治疗作用,但成本高、副作用大。研究能够有效、安全、低成本地预防及治疗阿片类毒品成瘾的药物已成为新药开发热点之一。
二甲双胍(Metformin),即1,1-二甲基双胍,为口服降血糖药,用于治疗成人非胰岛素依赖型糖尿病及部分依赖型糖尿病。对于肥胖型糖尿病患者,尚可利用其抑制食欲及肠吸收葡萄糖而减轻体重,其在临床上的应用已经超过50年,具有安全有效、降糖效果好的特点。二甲双胍的作用机制包括:抑制糖异生,减少肝糖输出;降低游离脂肪酸,改善胰岛素敏感性,恢复β细胞胰岛素分泌;促进葡萄糖转运体4基因表达,改善肌肉糖原合成,提高胰岛素敏感性等。最近研究发现,除了降血糖作用外,二甲双胍还具有多种药效,如抗肿瘤活性,心血管的保护作用等(Wang YW, He SJ, Feng X, Cheng J, Luo YT, Tian L, HuangQ. Metformin: a review of its potential indications. Drug Des Devel Ther.2017;11:2421-2429.)。此外,二甲双胍可以改善帕金森病中线粒体功能损伤以及其他症状(Fitzgerald JC, Zimprich A, Carvajal Berrio DA, Schindler KM, Maurer B,Schulte C, Bus C, Hauser AK, Kübler M, Lewin R, Bobbili DR, Schwarz LM,Vartholomaiou E, Brockmann K, Wüst R, Madlung J, Nordheim A, Riess O, MartinsLM, Glaab E, May P, Schenke-Layland K, Picard D, Sharma M, Gasser T, KrügerR. Metformin reverses TRAP1 mutation-associated alterations in mitochondrialfunction in Parkinson’s disease. Brain. 2017;140(9): 2444-2459. Katila N,Bhurtel S, Shadfar S, Srivastav S, Neupane S, Ojha U, Jeong GS, Choi DY.Metformin lowers α-synuclein phosphorylation and upregulates neurotrophicfactor in the MPTP mouse model of Parkinson's disease. Neuropharmacology.2017; 125:396-407)。二甲双胍还具有减少老年性痴呆的病理损伤作用(Niccoli T,Cabecinha M, Tillmann A, Kerr F, Wong CT, Cardenes D, Vincent AJ, Bettedi L,Li L, Grönke S, Dols J, Partridge L. Increased Glucose Transport into NeuronsRescues Aβ Toxicity in Drosophila. Curr Biol. 2016; 26(17):2291-300.Metformin treatment prevents amyloid plaque deposition and memory impairmentin APP/PS1 mice. Ou Z, Kong X, Sun X, He X, Zhang L, Gong Z, Huang J, Xu B,Long D, Li J, Li Q, Xu L, Xuan A. Brain Behav Immun. 2017; S0889-1591(17)30549-4)。二甲双胍增加线虫的寿命(Cabreiro F, Au C, Leung KY, Vergara-IrigarayN, Cochemé HM, Noori T, Weinkove D, Schuster E, Greene ND, Gems D. Metforminretards aging in C. elegans by altering microbial folate and methioninemetabolism. Cell. 2013;153(1):228-39. Martin-Montalvo A, Mercken EM, MitchellSJ, Palacios HH, Mote PL, Scheibye-Knudsen M, Gomes AP, Ward TM, Minor RK,Blouin MJ, Schwab M, Pollak M, Zhang Y, Yu Y, Becker KG, Bohr VA, Ingram DK,Sinclair DA, Wolf NS, Spindler SR, Bernier M, de Cabo R. Metformin improveshealthspan and lifespan in mice. Nat Commun. 2013;4:2192. De Haes W,Frooninckx L, Van Assche R, Smolders A, Depuydt G, Billen J, Braeckman BP,Schoofs L, Temmerman L. Metformin promotes lifespan through mitohormesis viathe peroxiredoxin PRDX-2. Proc Natl Acad Sci U S A. 2014;111(24) )。二甲双胍是否可以预防和/或治疗阿片类毒品成瘾尚未见报道。
发明内容
为了探索二甲双胍的新用途,本发明的第一目的是提供二甲双胍在制备预防和/或治疗阿片类毒品成瘾药物中的应用;第二目的是提供一种预防和/或治疗阿片类毒品成瘾的药物;第三目的是提供预防和/或治疗阿片类毒品成瘾的药物的制备方法,本发明的具体方案如下:
本发明涉及的二甲双胍在制备预防和/或治疗阿片类毒品成瘾的药物中的应用。
本发明涉及的预防和/或治疗阿片类毒品成瘾的药物,包括用量小于200 mg/kg的二甲双胍和药物上可接受的辅料,其中,辅料的质量百分比低于0.1%。
进一步地,所述辅料包括常规的填充剂、稀释剂、粘合剂、赋形剂、吸收促进剂、填充剂、表面活性剂或稳定剂。
进一步地,还包括香味剂、色素和甜味剂。
进一步地,所述药物为胶囊、丸剂、粉剂、片剂、粒剂、口服液或注射液。
本发明涉及的预防和/或治疗阿片类毒品成瘾的药物的制备方法,包括如下步骤:
步骤(1)200 mg/Kg二甲双胍的配制:
将4.6 mg二甲双胍溶于200 微升的无菌水中,之后给体重23 g小鼠灌胃,即得到200mg/Kg的二甲双胍给药剂量。
步骤(2)药物的制备:
在上述200 mg/Kg的二甲双胍中加入质量百分比为0.1%的辅料,即得到预防和/或治疗阿片类毒品成瘾的药物。
与现有技术相比,本发明的有益效果如下:
首次发现二甲双胍在制备预防和/或治疗阿片类毒品成瘾药物中的应用。
本发明的动物实验结果:(1)灌胃二甲双胍(200 mg/Kg)7天后,对小鼠进行条件位置偏爱实验。发现预先二甲双胍灌胃给药,能够拮抗吗啡所引起的位置偏爱行为。
与目前临床上常用的抗成瘾药物相比,本发明的药物具有以下优点:(1)疗效显著;(2)安全性高,无副作用,无成瘾性;(3)价格低廉,可以减轻病人的经济负担。
附图说明
下面结合附图对本发明作进一步详细说明,但不应看作对本发明的限制。
图1是二甲双胍拮抗吗啡所引起的位置偏爱行为的实验结果图。
具体实施方式
下面描述本发明的具体实施方式,所用方法如无特别说明均为常规方法。
实施例1二甲双胍抵抗吗啡诱发的条件性位置偏爱实验
1、采用的实验动物为:SPF级C57BL/6小鼠,雄性,7-8周龄,体重23 g,由重庆医科大学实验动物中心提供。小鼠单笼隔离饲养,饲喂专用饲料,自由饮食和饮水。
2、采用的药品为:二甲双胍(购于SIGMA-ALDRICH, Lot#LRAA8975,美国),盐酸吗啡注射液(东北制药集团公司沈阳第一制药厂)。
二甲双胍(200 mg/Kg)的配制方法:4.6 mg溶于200 微升的无菌水中体重23 g小鼠灌胃给药。
吗啡(20 mg/Kg)的配制方法:10 mg/ml的盐酸吗啡注射液46 微升,溶于54 微升的生理盐水中,体重23 g小鼠,腹腔注射给药。
位置偏爱行为检测装置:由两个大小完全相同的装置盒子组成(15×15×30 cm),每个盒子由两种不同的背景颜色,黑色盒子粗糙的地板,白色盒子光滑的地板,两个盒子中间由一个可以上下拉动的挡板隔开,验时将隔板向上拉,小鼠可以自由在两个盒子之间活动。
小鼠分成4组,分别为对照组(C)、吗啡组(M)、吗啡和二甲双胍组(M+Metformin)、二甲双胍组(Metformin),每组10只小鼠。
实验第1-7天,每天给予M+Metformin组和Metformin组小鼠二甲双胍(200 mg/Kg,溶于无菌水)灌胃给药,第5-6天,二甲双胍给药后2小时,将所有小鼠放到黑白箱中自由活动适应15 分钟,第7天,二甲双胍给药后先将小鼠放到黑白箱中适应5分钟,然后分别记录每只小鼠15分钟内在黑箱中停留的时间,确定小鼠天然偏爱黑箱还是白箱。
如果偏爱黑箱,则小鼠注射完吗啡之后放入白箱,此时白箱为伴药箱,黑箱为非伴药箱。第8、10、12、14天,在二甲双胍给药后2小时,M组和M+Metformin组小鼠腹腔注射吗啡(20 mg/kg,溶于生理盐水)后放入伴药箱,适应15分钟,C组和Metformin组给予等量生理盐水。第9、11、13、15天,所有小鼠在给予二甲双胍2小时后,腹腔注射等量生理盐水后放入非伴药箱,适应15分钟。第16天,将黑白箱中间的挡板打开,使小鼠在其中自由活动5分钟,然后记录15分钟内小鼠在非伴药箱内停留的时间,以评估小鼠吗啡成瘾模型是否构建成功。
如图1所示,M组小鼠经给药训练后偏爱于伴药箱(p<0.001,与C组小鼠对比);而M+Metformin组小鼠经二甲双胍预先灌胃后,可以拮抗吗啡成瘾所致的偏爱性(p<0.01,与M组小鼠对比)。由此可见,预先二甲双胍灌胃给药能够拮抗吗啡所引起的位置偏爱行为。
二甲双胍在制备预防和/或治疗阿片类毒品成瘾药物中的应用是发明人的首次发现,无论是二甲双胍单独作为活性成分制成药剂使用,还是利用二甲双胍预防及治疗阿片类毒品成瘾的作用与其他活性成分配合使用制成药剂的应用,均在本发明的保护范围之内。
Claims (6)
1.二甲双胍在制备预防和/或治疗阿片类毒品成瘾的药物中的应用。
2.一种预防和/或治疗阿片类毒品成瘾的药物,其特征在于:包括用量小于200 mg/kg的二甲双胍和药物上可接受的辅料,其中,辅料的质量百分比低于0.1%。
3.根据权利要求2所述的药物,其特征在于:所述辅料包括常规的填充剂、稀释剂、粘合剂、赋形剂、吸收促进剂、填充剂、表面活性剂或稳定剂。
4.根据权利要求3所述的药物,其特征在于:还包括香味剂、色素和甜味剂。
5.根据权利要求2-4之一所述的药物,其特征在于:所述药物为胶囊、丸剂、粉剂、片剂、粒剂、口服液或注射液。
6.一种预防和/或治疗阿片类毒品成瘾的药物的制备方法,其特征在于:包括如下步骤:
步骤(1)200 mg/Kg二甲双胍的配制:
将4.6 mg二甲双胍溶于200微升的无菌水中,用于体重为23 g小鼠,即得到200 mg/Kg的二甲双胍;
步骤(2)药物的制备:
在上述200 mg/Kg的二甲双胍中加入质量百分比为0.1%的辅料,即得到预防和/或治疗阿片类毒品成瘾的药物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810067882.1A CN108159032A (zh) | 2018-01-24 | 2018-01-24 | 二甲双胍在制备预防和/或治疗阿片类毒品成瘾药物中的应用和药物及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810067882.1A CN108159032A (zh) | 2018-01-24 | 2018-01-24 | 二甲双胍在制备预防和/或治疗阿片类毒品成瘾药物中的应用和药物及制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108159032A true CN108159032A (zh) | 2018-06-15 |
Family
ID=62515264
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810067882.1A Pending CN108159032A (zh) | 2018-01-24 | 2018-01-24 | 二甲双胍在制备预防和/或治疗阿片类毒品成瘾药物中的应用和药物及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108159032A (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1192903A (zh) * | 1997-03-07 | 1998-09-16 | 潘心富 | 一种双胍基氢化嘌呤环类化合物的戒毒药 |
CN1845907A (zh) * | 2003-09-05 | 2006-10-11 | 埃科特莱茵药品有限公司 | 胍衍生物 |
CN102266312A (zh) * | 2011-06-23 | 2011-12-07 | 昆明理工大学 | 替普瑞酮在制备预防和/或治疗阿片类毒品成瘾药物中的应用 |
CN104721175A (zh) * | 2015-03-30 | 2015-06-24 | 南京医科大学 | 二甲双胍在镇痛药物领域的新用途 |
-
2018
- 2018-01-24 CN CN201810067882.1A patent/CN108159032A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1192903A (zh) * | 1997-03-07 | 1998-09-16 | 潘心富 | 一种双胍基氢化嘌呤环类化合物的戒毒药 |
CN1845907A (zh) * | 2003-09-05 | 2006-10-11 | 埃科特莱茵药品有限公司 | 胍衍生物 |
CN102266312A (zh) * | 2011-06-23 | 2011-12-07 | 昆明理工大学 | 替普瑞酮在制备预防和/或治疗阿片类毒品成瘾药物中的应用 |
CN104721175A (zh) * | 2015-03-30 | 2015-06-24 | 南京医科大学 | 二甲双胍在镇痛药物领域的新用途 |
Non-Patent Citations (1)
Title |
---|
乐凯、文若剑: "阿片成瘾中的神经免疫机制", 《江汉大学学报(自然科学版)》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230414572A1 (en) | Prevention or treatment of sleep disorders using dexmedetomidine formulation | |
WO2011075539A2 (en) | Treatment of obesity or diabetes with bile acid sequestrants | |
AU2020267217B2 (en) | Therapeutic methods employing noribogaine and related compounds | |
CN105636584A (zh) | 使用维生素b组合物促进胃肠系统动力的方法 | |
JP5116071B2 (ja) | D−アロースおよびd−プシコースの抗神経因性疼痛効果の利用 | |
CA2414500A1 (en) | Agonist-aversive combination medicines | |
CN116940362A (zh) | 在慢性ssri方案后使用苯二氮䓬增加对裸盖菇素的敏感性 | |
WO2016061554A1 (en) | Synergistic composition of known, safe pharmaceuticals for use in insomnia and a method of treatment thereof | |
CN108159032A (zh) | 二甲双胍在制备预防和/或治疗阿片类毒品成瘾药物中的应用和药物及制备方法 | |
US20150110865A1 (en) | Cns stimulant and opioid receptor antagonist combination as a non-addictive, non-aversive and synergistic anti-obesity treatment | |
KR101793308B1 (ko) | 5-ht3 수용체 길항제인 사인 추출물을 포함하는 구토 또는 설사의 치료용 조성물 | |
WO2010110428A1 (ja) | 掻痒の予防及び/または治療剤 | |
US20180221373A1 (en) | Method of treating insomnia | |
CN108159031A (zh) | 二甲双胍在制备预防和/或治疗苯丙胺类毒品成瘾药物中的应用和药物及制备方法 | |
JP5809005B2 (ja) | Pde5阻害剤含有医薬組成物 | |
Ivnitsky et al. | Promotion of the toxic action of cyclophosphamide by digestive tract luminal ammonia in rats | |
AU2012276476B2 (en) | Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation | |
WO2007122419A2 (en) | Therapeutic method for glycaemic control | |
US9358265B2 (en) | Plant based formulation for the prevention and management of irritable bowel syndrome (IBS) | |
CN110327345B (zh) | 一种防治缺血性脑中风的磷酸二酯酶9a抑制剂的用途 | |
Borisov et al. | Treatment of chronic recurrent vulvovaginal candidiasis with fluconazole (fungolon--Actavis) | |
US9877951B2 (en) | Method for treating dementia | |
KR20140112266A (ko) | 나복자 추출물을 포함하는 구토 또는 설사의 치료용 조성물 | |
JP5704853B2 (ja) | Pde5阻害剤とジャショウシを含有する医薬組成物 | |
JP5587671B2 (ja) | Pde5阻害剤と反鼻とを含有する医薬組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180615 |